Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01279798|
Expanded Access Status : No longer available
First Posted : January 19, 2011
Last Update Posted : March 1, 2011
|Condition or disease||Intervention/treatment|
|Non-small Cell Lung Cancer||Biological: Lucanix® (belagenpumatucel-L)|
The primary objective of this study is to increase the overall survival of the study subjects by providing expanded access to Lucanix. Overall survival and progression-free survivals will be compared with historical controls.
The secondary objectives of this study are:
- Evaluate the best overall tumor response.
- Evaluate progression-free survival (PFS).
- Evaluate treatment toxicity.
|Study Type :||Expanded Access|
|Official Title:||Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) in Advanced Non-small Cell Lung Cancer.|
- Biological: Lucanix® (belagenpumatucel-L)
Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.Other Name: Lucanix
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01279798
|United States, California|
|Innovative Research Center of California|
|San Diego, California, United States, 92103|